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Fluorescence lifetime measurements can provide quanti-
tative readouts of local fluorophore environment and
can be applied to biomolecular interactions via Fo¨rster
resonant energy transfer (FRET). Fluorescence lifetime
imaging (FLIM) can therefore provide a high content
analysis (HCA) modality to map protein-protein interac-
tions (PPIs) with applications in drug discovery, systems
biology and basic research. We present here an auto-
mated multiwell plate reader able to perform rapid un-
supervised optically sectioned FLIM of fixed and live
biological samples and illustrate its potential to assay
PPIs through application to Gag protein aggregation
during the HIV life cycle. We demonstrate both hetero-
FRET and homo-FRET readouts of protein aggregation
and report the first quantitative evaluation of a FLIM
HCA assay by generating dose response curves through
addition of an inhibitor of Gag myristoylation. Z 0 factors
exceeding 0.6 are realised for this FLIM FRET assay.
Fluorescence lifetime plate map with representative
images of high and low FRET cells and corresponding
dose response plot.
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1. Introduction
The trend towards automated high content assays,
particularly for systems biology and drug discovery,
has stimulated the development of automated fluo-
rescence microscopy systems to image sample arrays,
e.g. in microtitre plates [1, 2]. Today’s commercially
available HCA instruments predominantly employ
fluorescence intensity imaging in one or more spec-
tral channels to map the relative distribution and co-
localization of labelled proteins with subcellular re-
solution. There is increasing interest in harnessing
fluorescence-based readouts for protein-protein in-
teractions (PPIs) [3] with FRET measurements now
commonplace in biology laboratories. However, to
date, this has not been widely taken up for drug dis-
covery. FRET entails exciting a “donor” fluorophore
and observing the consequences of a transfer of the
excitation energy to an appropriate “acceptor” fluo-
rophore. This energy transfer is mediated by a direct
dipole–dipole interaction and only occurs between
fluorophores separated by less than ~10 nm [4], en-
abling the detection and observation of binding of
appropriately labelled proteins, either as end points
in fixed cells or as dynamic events in live cells. FRET
can also be used to read out conformational changes
of a single molecule labeled with both donor and ac-
ceptor fluorophores and this is the basis of a range
of genetically expressed intracellular biosensors that
enable in vivo readouts of analytes such as calcium
[5], potassium [6] and chloride [7] ions and signalling
molecules such as IP3 [8], PIP2 [9] and calpain [10],
among others [11]. Imaging techniques that can map
molecular interactions by reading out FRET are
therefore desirable to reveal the spatio-temporal or-
ganization of biomolecular interactions within cells,
for example during cell signalling. Unfortunately
conventional (manual) FRET microscopy is too
time-consuming and labour-intensive for high
throughput applications, e.g. screening libraries of re-
agents or siRNA gene knockdowns, and so the de-
velopment of practical HCA FRET instrumentation
is desirable for drug discovery and basic research.
While there are many approaches to map FRET
[12], the most widely used are spectral ratiometric
imaging and FLIM. The former can be easier to im-
plement on existing instrumentation, requiring fewer
detected photons and providing faster imaging than
FLIM, but the latter can provide more quantitative
readouts and requires less in the way of control/cali-
bration samples. Spectral ratiometric FRET suffers
from uncertainties associated with relative donor/ac-
ceptor concentrations, the spectral response – in-
cluding the instrument and the sample itself (inner
filter effect) – and cross-talk (e.g. direct excitation
of the acceptor and spectral bleed-through in the de-
tection channels). These issues are mitigated when
using single molecule FRET biosensors (with known
stoichiometry) to follow dynamics (i.e. relative
changes) but quantitative FRET measurements re-
quire additional control samples, labelled with donor
only and acceptor only, to calibrate the system. Spec-
tral ratiometric FRET measurements can then yield
the relative proportion of donor and acceptor mole-
cules and the effective FRET efficiency (i.e. the pro-
duct of the actual FRET efficiency and the fraction
of FRETing donor/acceptor molecules) [13]. To ob-
tain the fractions of the FRETing donor and accep-
tor populations, it is necessary to independently de-
termine the actual FRET efficiency – either by
measuring further (positive control) samples or by
using other methods, such as acceptor photobleach-
ing or FLIM.
Polarisation resolved anisotropy imaging is an al-
ternative ratiometric technique to map FRET that
exploits the decrease in fluorescence anisotropy of
the acceptor in the presence of FRET [14]. This
technique can reach similar imaging speeds to spec-
tral ratiometric imaging and has recently been imple-
mented in an automated multiwell plate reader [15].
While it provides high contrast for detecting FRET,
it is also sensitive to spectral cross-talk (e.g. direct
excitation of the acceptor), requires calibration to
account for polarisation cross talk and is less able to
quantitate changes in FRET efficiency [15, 16].
Fluorescence lifetime measurements are indepen-
dent of fluorophore concentration, excitation and de-
tection efficiencies and the impact of scattering and
sample absorption [17]. Fitting fluorescence decay
profiles to an appropriate multi-exponential decay
model can directly yield the FRETing fraction of the
donor population and fluorescence lifetime-based
FRET measurements can be readily compared
across different instruments. FLIM can also be used
to map other variations in local fluorophore environ-
ment, e.g. reporting on the concentration of analytes
such as calcium using fluorescent dyes [18] or on
physical changes such as temperature [19] or mem-
brane lipid order [20]. Furthermore, FLIM readouts
can be compared between cell-based assays and in
vivo FRET measurements and thus potentially be
translated along the drug discovery pipeline to ani-
mal models [21] since they do not require calibration.
In spite of these advantages, FLIM has not yet made
a significant impact on drug discovery, partly due to
a lack of available FLIM instrumentation for auto-
mated multiwell plate readouts. FLIM is often imple-
mented using laser scanning microscopes with time
correlated single photon counting (TCSPC) [22–24],
for which the sequential pixel acquisition of this ap-
proach typically results in data acquisition times of
10’s–100’s of seconds per cell to acquire sufficient
detected photons, depending on the sample bright-
ness, with the accuracy of fluorescence lifetime deter-
mination being proportional to the square root of
the number of photons detected [25]. Such acquisi-
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tion times are impractical for HCA and, if the excita-
tion intensity is increased to permit much faster im-
aging, there are significant issues with photobleach-
ing and phototoxicity. Recently an imaging multiwell
plate reader utilising multiphoton TCSPC FLIM was
reported [15] but this was for secondary measure-
ments following a first pass by steady-state polarisa-
tion-resolved anisotropy imaging as TCSPC FLIM
required 12.5 hours to image 50 wells at 5 fields of
view (FOV) per well – compared to 43 minutes to
image the same FOVs with polarisation.
Although TCSPC FLIM may ultimately become
suitable for HCA with the development of more sen-
sitive detectors and multichannel excitation/detec-
tion schemes, its implementations to date have en-
couraged a perception that FLIM HCA is not
practical. We therefore believe that it is important to
demonstrate the advantages and practicality of
FLIM for FRET assays of PPIs and here present a
quantitative evaluation of FRET assays undertaken
on an optically sectioning FLIM multiwell plate
reader utilising wide-field time-gated imaging that is
able to automatically read a 96 well plate in 10’s
minutes [21] (including sample movement and auto-
matic focusing).
Wide-field detection permits rapid imaging with
significantly reduced photobleaching compared to la-
ser scanning microscopy and can be implemented in
the time domain using a gated optical image intensi-
fier or in the frequency domain using a sinusoidally
modulated optical image intensifier [26] or a CMOS
camera with modulated gain [27]. Frequency domain
and time domain FLIM can provide equivalent data,
but there are performance trade-offs for specific im-
plementations of both approaches. We note that the
first HCA instrument for unsupervised FLIM of
multiwell plate sample arrays [28] utilised wide-field
frequency domain FLIM in a non-sectioning micro-
scope, elegantly demonstrating the potential of auto-
mated FLIM-FRET and the statistical analysis of
FLIM array data. Subsequently a wide-field fre-
quency domain FLIM plate reader has been applied
to image post translational modifications (tyrosine
phosphorylation) in situ – specifically uncovering
components that transduce signals from epidermal
growth factor receptors [29] and impressively illus-
trating the potential impact of FLIM HCA when
combined with automated sample preparation.
These wide-field FLIM plate readers, however, did
not benefit from optical sectioning, which can im-
prove quantitative readouts by rejecting contribu-
tions from out-of-focus fluorescence.
Our realization of rapid FLIM and FRET for
HCA has been implemented in the time domain
using a gated optical image intensifier to provide
wide-field time-gated imaging and incorporated a
quasi-wide-field Nipkow (“spinning disc”) micro-
scope unit to provide optical sectioning [30]. This ap-
proach has realised optically sectioned FLIM-FRET
of live cells at up to 10 frames/second [31] and in a
previous study we illustrated its effectiveness in a
modified commercially available plate reader (GE
Healthcare IN Cell 1000), demonstrating an assay of
HIV-1 Gag aggregation in live HEK293T cells [21].
HIV-1 Gag proteins are the molecular machine
responsible for orchestrating the assembly of nascent
HIV-1 virions at the cell membrane [32]. Even in the
absence of other viral proteins and enzymes, expres-
sion of HIV-1 Gag alone in cells results in the pro-
duction of viral like particles (VLPs) that are similar
to immature HIV-1 virions and are often used as a
model system for the late stages in the HIV-1 life-
cycle. Labeling the C-terminal of HIV-1 Gag pro-
teins with fluorescent protein tags enables their dis-
tribution to be visualized and VLP formation can be
assayed using FLIM-FRET to report on the aggrega-
tion of appropriately labelled Gag proteins (e.g. sto-
chastically labelled with CFP and YFP). Membrane
binding of HIV-1 Gag is a prerequisite for virion as-
sembly and is driven by a ‘myristic switch’ mechan-
ism whereby a sequestered myristic acid moiety (a
co-translational modification to the Gag protein)
present in Gag monomers is exposed to the solvent
upon oligomerisation of two or more Gag proteins,
resulting in an increase in hydrophobicity that drives
membrane binding [33]. This ‘myristic switch’ me-
chanism provides an opportunity to interfere with
virion formation and hence is a potential target for
inhibitors of HIV-1 assembly.
Here we present an improved FLIM FRET assay
of Gag protein aggregation, this time in HeLa cells
that provide a superior biological host, and show
how our automated FLIM plate reader can discrimi-
nate different biomolecular processes as we manipu-
late the HIV-1 Gag protein interactions through the
use of myristic acid negative mutants that are unable
to bind the plasma membrane [33]. Furthermore we
apply an inhibitor of myristoylation (NMT inhibitor
DDD85646 [34]) to permit, for the first time, a quan-
titative evaluation of FLIM FRET assay perfor-
mance using dose response curves and calculation of
Z0 factors. We use this metric to compare the assay
performance of hetero-FRET and homo-FRET read-
outs of the Gag protein interactions and present the
first FLIM assay of protein aggregation based on
homo-FRET.
2. Materials and methods
2.1 Automated FLIM plate reader
Figure 1 presents a schematic of the automated
FLIM plate reader, which is built around a wide-
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field microscope (Olympus IX81-ZDC) that incor-
porates an optical autofocus system as well as auto-
mated stage movement and changing of excitation
filters. Prior to FLIM acquisition, the plate reader
can perform an automatic cell finding (“pre-find”)
scan to rapidly identifiy and map FOV containing
suitable cells for the FLIM assay. This typically
takes ~30 minutes to find 4 FOV per well. A num-
ber of pre-find routines are available including
using a lower magnification objective for increased
speed and performing a pre-find in two spectral
channels to ensure that only cells expressing both
donor and acceptor plasmids are imaged. High
speed, optically sectioned FLIM was implemented
as outlined previously [30] via a Nipkow disc unit
(Yokogawa Electric Corporation; CSU-X ML1) with
excitation being provided by a fibre-laser pumped
supercontinuum source (Fianium UK Ltd, SC 400-
6) with the resultant fluorescence being detected
using a gated optical intensifier (Kentech Instru-
ments; model HRI) read out by a cooled CCD (Ha-
mamatsu Photonics; model Orca ER II). All images
were acquired using a 40 long working distance
air objective (Olympus, LUCPLFLN 40) with an
NA of 0.6.
2.2 Cell preparation
All work was carried out using HeLa cells main-
tained in DMEM (Gibco) supplemented with 10%
fetal calf serum (Gibco), 2.5% antibiotic and 2.5%
L-glutamine. Cells were maintained at 37 C, 5%
CO2 and grown until 80–90% confluent in T75
flasks (Corning) before passaging using trypsin to
detach the cells.
Plasmids were provided by Pfizer Limited. The
Gag fusion proteins were ligated into pcDNA3.1(þ)
expression vector (Invitrogen). Generation of the
Myr()Gag fusion proteins was achieved through the
point mutation of the first N-terminal glycine residue
within the Gag protein.
Cells were seeded in 96 well plates (Greiner,
mclear) 24 hours before the start of transfections.
Prior to transfection, cells were transferred from
growth media, washed in phosphate buffered saline
(PBS) and placed in Optimem 1 reduced serum
media (Gibco). Transfections were performed using
Lipofectamine 2000 (Invitrogen). Transfection mixes
were prepared following manufacturer’s instructions
using a total of 150 ng of plasmid DNA per well with
a 2 : 1 ratio of lipids to DNA. The transfection mixes
were left on the cells for 6 hours before removal.
Cells were then washed in PBS and the media re-
placed with growth media. The addition of NMT in-
hibitor doses was performed at the same time as the
lipofection, with the NMT inhibitor being diluted
into the Optimem 1 used to seed the cells prior to
transfection. Transfections were then carried out as
described above. After 24 hours, cells were washed
in PBS and fixed in 4% paraformaldehyde for
15 minutes. Cells were then washed twice in PBS to
remove the paraformaldehyde and imaged in PBS at
room temperature.
2.3 Data analysis
The fluorescence decay profiles of the CFP donor
were analysed by fitting the data to a single expo-
nential decay model on a pixel-wise basis or by auto-
matically defining regions of interest (ROIs) contain-
ing the cell membranes and fitting the binned pixels
from each ROI to an exponential decay model. The
fitting software is written in-house and will be de-
scribed in detail in a future publication. Briefly it uti-
lises a standard Levenberg-Marquardt non-linear
least squares (NLLS) fitting algorithm incorporating
reference reconvolution whereby the measurement
of a short lifetime dye standard (DASPI) is used to
account for the instrument response function (IRF)
within the fitting algorithm.
The automatic image segmentation was performed
using a routine developed in-house (MATLAB) that
Figure 1 Schematic of FLIM multiwell plate reader. Tun-
able pulsed (~10 ps) excitation is provided by a superconti-
nuum laser source coupled into the Nipkow disc unit that
provides rapid scanning multipoint excitation. The result-
ing fluorescence passes through a spectral filter to the
gated optical intensifier (HRI), which is gated at user-de-
fined delays after the arrival of the excitation pulses and is
read out using a cooled CCD camera. The motorised stage
and autofocus allows fully automated location and subse-
quent imaging of samples.
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uses a size-tuned nonlinear top-hat function [35].
This method transforms the image pixel by pixel,
enhancing the brightness of a pixel if its close vici-
nity is also bright and its distant vicinity is dim. A
user-defined threshold is then applied to the trans-
formed image and the resultant binary image is
smoothed using standard Matlab functions and spa-
tially distinct regions are identified. These regions
are then size-sieved to remove objects smaller than a
user-defined threshold. The cell segmentation masks
are then eroded by a user-defined number of pixels
(corresponding to the width of the cell membrane)
and the the difference between the two binary
images provides a binary membrane mask to apply
to the FLIM data prior to fitting.
3. Results and discussion
The automated FLIM plate reader was applied to as-
say HIV-1 Gag protein aggregation in HeLa cells,
imaging 4 fields of view (FOV, 672 512 pixels cor-
responding to 309 235 mm in the image plane) of
FLIM-FRET data per well, with ~30 s/FOV average
FLIM acquisition time following the pre-find scan.
Figure 2 shows the results from a plate where the
wells in each row were seeded with cells expressing
a different preparation of Gag protein constructs, as
indicated in the plate map (Figure 2a).
The lifetime data was analysed using the in-house
fitting software to fit pixel-wise to a single exponen-
tial decay model, thereby providing an effective
Figure 2 (a) plating scheme. (b) plate map of mean well lifetimes (averaged over 4 FOV per well) from pixel-wise fitting
to single exponential decay model. Lifetime scale bar 3200 ps (red) to 2000 ps (blue). White squares indicate that no cells
were found in that well by the automated microscope. Typical images of HeLa cells transfected with Myr()Gag-CFP and
Gag-CFP are shown in (c) and (d) respectively. (e) segmentation mask applied to FOV shown in (c) preferentially select-
ing the plasma membrane (typical ROI comprises ~1200–1500 pixels). (g) box plots of lifetime  SD for each biological
construct with all ROI pixels binned and fitted to single exponential decay model on a per cell basis. (h) mean lifetimes
per condition  SD when data was intensity thresholded and fitted to a single exponential decay pixelwise (red). Auto-
matic image segmentation to select cells (black) or just cell membranes (green) with the resulting data fitted using a single
exponential decay model on a per ROI basis.
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“mean lifetime” per pixel. Figure 2b is a false colour
plate map of the average lifetime per well (cal-
culated across all pixels and FOVs) and Figures 2c
and d present typical optically sectioned FLIM
images of HeLa cells expressing Myr()Gag-CFP and
Gag-CFP respectively (thresholded to a minimum of
200 photons acquired per pixel). Figure 2f presents
the composite histograms of CFP lifetime for each of
the sets of repeat wells (i.e. for each of the biological
preparations). Inspection of the FLIM images indi-
cates that higher levels of FRET (lower lifetimes)
occur near the plasma membrane, as expected for
VLP formation [32]. Figure 2e shows an image seg-
mentation mask – along with an example of a single
exponential decay fit of the indicated ROI – gener-
ated by applying an automatic plasma membrane
segmentation algorithm to the data to select regions
where the VLPs are being formed and Figure 2g
presents box plots of the mean fluorescence lifetime
for each biological preparation, calculated by bin-
ning the time-resolved data for each of the (near
membrane) ROIs independently and fitting each to
a single exponential decay model. Figure 2h displays
the results from the two fitting methods on common
axes. We also present results obtained when the cell
segmentation algorithm was applied to segment
whole cells instead of just cell plasma membranes.
Differences can be seen between the application of
the intensity threshold and the application of the
segmentation algorithm to select entire cells. These
differences arise due to inclusion of FRETing cell
debris in the intensity thresholded case. This FRET-
ing cell debris is a direct result of VLP formation
and budding through the cell membrane, damaging
it in the process and reducing its integrity, eventually
leading to the cell breaking apart. Finally, membrane
segmentation only has a noticeable effect for the
constructs that are expected to aggregate, and hence
FRET, at the plasma membrane of the cells, for
which it increases the dynamic range of the assay.
Statistically different mean lifetimes are ob-
served (significance level p < 0.05) for each of the
plasmid combinations after application of an ANO-
VA test with multiple mean comparisons (with the
exception of Myr()Gag-CFP þ Myr()Gag-YFP and
Myr()Gag-CFP þ Gag-YFP). As expected, the mean
lifetime of wild-type Gag labelled with CFP de-
creases (by ~200 ps) due to FRET when co-ex-
pressed with the Gag-YFP acceptor construct com-
pared to when it is expressed alone. The mean
lifetime of the CFP attached to the Gag protein is
itself lower than for the CFP attached to the mu-
tated Myr()Gag that does not form VLPs. This low-
er mean Gag-CFP lifetime can be attributed to
homo-FRET between CFP fluorophores in the
VLPs [36] and possibly to the different refractive in-
dex at the plasma membrane. We note that homo-
FRET does not usually result in a change in fluor-
escence lifetime but for CFP it is thought to occur
as a consequence of interactions between different
states of this complex fluorophore. The prospect of
a homo-FRET readout of protein aggregation is at-
tractive since it increases the opportunities for mul-
tiplexing with other readouts as well as simplifying
transfection procedures and minimising reagent use
for HCA. The mean lifetime of the Gag-CFP co-ex-
pressed with mutated acceptor protein (Myr()Gag-
YFP) is again slightly lower than for the Gag-CFP
expressed alone. This is because, although the
Myr()Gag-YFP does not contribute to VLPs at the
plasma membrane by itself, it can still dimerise with
wild-type Gag-CFP protein in the cytoplasm and be
‘rescued’ into VLPs, providing acceptors for hetero-
FRET. Similarly, the mutated Myr()Gag-CFP does
not form VLPs and so any FRET in the cells ex-
pressingMyr()Gag-CFP þ Gag-YFP must arise from
its dimerisation with Gag-YFP in the cytoplasm fol-
lowed by such dimers being brought into the VLPs.
Finally, the cells expressing mutated Myr()Gag-CFP
and Myr()Gag-YFP should not form VLPs but the
mean CFP lifetime is slightly lower than for the
cells expressing Myr()Gag-CFP alone, which we at-
tribute to FRET occurring when the Gag proteins
dimerise in the cytoplasm.
3.1 Characterisation of FLIM based HIV-1
Gag aggregation assay
This readout for Gag VLP formation can be used to
assay the efficacy of compounds to inhibit HIV-1 as-
sembly and to generate dose response curves, which
themselves can be used to quantify the relative per-
formance of assays. The enzymes N-myristoyltrans-
ferase 1 and 2 (HsNMT 1 and 2) are responsible for
the co-translational addition of a myristic acid moi-
ety to proteins within cells and compounds that
block the action of these enzymes should inhibit
VLP formation. We applied the NMT inhibitor
DDD85646 [34] to evaluate FLIM FRET Gag VLP
formation assays using hetero-FRET in cells co-
transfected with Gag-CFP and Gag-YFP. We fol-
lowed standardized pharmaceutical industry guide-
lines [37] to ensure the assay is robust and to ac-
count for experimental factors such as pipetting
errors, plate edge effects, spatial uniformity and drift
over time that could impact the assay quality.
The assay characterisation experiments involved
the production of three 96-well plates that were pre-
pared separately and imaged on different days to
accurately replicate the situation of running a
compound screen. These plates were prepared using
a positive control compound (NMT inhibitor
DDD85646) known to act on the target of interest,
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added column-wise at three different concentrations:
Low (~EC20), Medium (~EC25-EC75) and High
(~EC80), with the order of addition changing be-
tween the plates (e.g. Plate 1 has the compound
added in the repeating pattern high, medium, low
and plate 2 has the compound added in the repeat-
ing pattern low, high, medium etc).
Figure 3 shows the resultant lifetime plate maps
from this assay characterisation study along with
plots of lifetime variation for each condition either
plotted column-wise (from left to right) or row-wise
(from top to bottom). Data was fitted by applying an
intensity threshold and fitting pixel-wise to a single
exponential decay model across all acquired fields of
view.
Inspection of the plate maps and plots indicates
that no systematic drift or edge effects are present,
showing that both the protocol used to prepare the
plates and the imaging system introduce no spatial
bias with regards to sample position on the plate.
Slight differences in the reported lifetimes per condi-
tion are observed between the three plates for the
high and medium doses of compound, but a consis-
tent lifetime of around 2530 ps is seen for the low
dose of the compound across all three plates. This
indicates that the small differences between the
plates are most likely to be caused by pipetting er-
rors made during the manual preparation of the
plates. This reproducibility is highlighted further
when the percentage inhibition is calculated for the
medium dose relative to the high and low dose for
each plate, which results in inhibition percentages of
73%, 74% and 75% for plates 1, 2 and 3 respec-
tively.
3.2 FLIM based dose response curves
We then assayed the dose response of NMT inhibi-
tor DDD85646 using both homo-FRET and hetero-
FRET readouts by seeding a well plate with cells
either expressing Gag-CFP alone or co-expressing
Gag-CFP and Gag-YFP. These cells were incubated
with concentrations of the NMT inhibitor varying
from 10 mM to 0.001 mM (over columns 2–10), as in-
dicated in the plate scheme in Figure 4a. Figure 4b
presents the map of mean CFP lifetimes for each
well (fitted to a single exponential decay model),
showing the general trend of increasing lifetime (de-
creasing FRET) with increasing NMT inhibitor dose
for both the homo-FRET (Gag-CFP only) case, and
the hetero-FRET (Gag-CFP þ Gag-YFP) case.
Figures 4c and d present the hetero-FRET and
homo-FRET dose response curves, for which all the
pixel lifetimes in the repeat wells (each well with
4 FOVs imaged, total FLIM acquisition time 3 hrs
15 mins) were averaged for each concentration of
Figure 3 Assay characterisation plates. (a) & (b) plate map of mean well lifetimes (averaged over 4 FOV per well) from
pixel-wise fitting to single exponential decay model and mean lifetimes plotted column-wise for each condition and row-
wise for each condition for plate 1. (c) & (d) plate map and mean lifetime plots (column-wise and row-wise) for plate 2.
(e) & (f) plate map and mean lifetime plots (column-wise and row-wise) for plate 3. White wells indicate that no cells were
found by the auto find routine. Wells D6 and D7 were used for background and IRF.
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NMT inhibitor. A measure of assay performance
may be obtained by calculating the Z0 parameter
[38], which uses the differences in the mean values
of the positive and negative controls and their rela-
tive spreads to generate a single value metric of as-
say quality. Typically a Z0 value of greater than 0.4 is
considered desirable for a screen or assay to be use-
ful. Here we find that for the homo-FRET assay of
Gag protein aggregation with pixel-wise fitting we
obtain a Z0 of 0.65 while for the hetero-FRET assay
we find a Z0 of 0.35. We note, however, that for the
hetero-FRET assay, our automated prefind process
failed to identify any suitable cells in wells 11E and
11F and that in wells 11G and 11H it found far fewer
cells than normal, which explains the lower calcu-
lated Z0 value for the hetero-FRET dose response.
If we instead use the hetero-FRET data from co-
lum 9 as the negative control, then we obtain a
Z0 ¼ 0.79, which represents a lower limit on the true
value.
Figures 4e and f display box plots resulting from
automatic image segmentation and binning of pixels
in the membrane ROIs for all the FOV and repeat
wells at each NMT inhibitor concentration – with
the automatic image segmentation typically resulting
in 60–100 cells per condition. At high doses of NMT
inhibitor, the membrane ROI segmentation makes
little difference (since there should be negligible
Gag protein binding at the membrane) but at low
doses this image segmentation lowers the observed
mean lifetime and increases the dynamic range of
the assay, resulting in Z0 values of 0.67 and 0.11 for
the homo-FRET and hetero-FRET readouts respec-
tively. Again the lower Z0 observed for the mem-
brane segmented hetero-FRET case is due to the
fact that cells were only found in two wells. As be-
fore, if we instead use column 9 as the negative con-
trol for hetero-FRET then we calculate a lower limit
for Z0 of 0.82.
Figure 4 (a) plating scheme. Region A2-D10 contained HeLa cells transfected with WT Gag-CFP with varying amounts of
NMT inhibitor (column 2: 10 mM to column 10: 0.001 mM) and region E2-H10 contained HeLa cells transfected with Gag-
CFP þ Gag-YFP with the same NMT inhibitor concentration range as region A2-D10. Column 1 contains HeLa cells
transfected with a mutated form of the HIV Gag protein (rows A–D: Myr()Gag-CFP, rows E–H: Myr()Gag-
CFP þ Myr()Gag-YFP) that do not form VLPs. Column 11 contains HeLa cells transfected with Gag-CFP (rows A–D) or
Gag-CFP þ Gag-YFP (rows E–H) that had been dosed with vehicle (DMSO) only. (b) mean well lifetime plate map
resulting from a pixel-wise single exponential fit, lifetime scale 3000 ps (red) to 2200 ps (blue). (c) and (d) dose dependent
curves ( SD) of pixel lifetimes averaged over all repeat wells for cells transfected with Gag-CFP only and Gag-
CFP þ Gag-YFP respectively. (e) and (f) dose dependent box plots ( SD) for pixels in segmented membrane ROIs,
binned and fitted to a single exponential decay model for cells expressing Gag-CFP only and Gag-CFP þ Gag-YFP respec-
tively.
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3.3 Estimation of dose response of aggregat-
ing Gag population fraction
We also applied global binning [39, 40], to demon-
strate the potential for FLIM FRET to be used
to quantify the changes in the population fraction of
FRETing donors that underlies the observed
changes in effective fluorescence lifetime obtained
from fitting to a single exponential decay model. We
applied global binning to both the Gag-CFP dose re-
sponse (using Myr()Gag-CFP as a positive control)
and the co-transfected Gag-CFP & Gag-YFP dose
response (using Myr()Gag-CFP and Myr()Gag-YFP
as a positive control). In each case, t1 was fixed to
the value obtained from a single exponential fit of
the positive control wells (column 1) to provide the
non-FRETing donor lifetime. The corresponding val-
ues for t2 were then determined using a double ex-
ponential fit to the globally binned decay from each
dose response (transfected with Gag-CFP and co-
transfected with Gag-CFP and Gag-YFP respec-
tively), given by:
IðtÞ ¼ Iðt ¼ 0Þ½1 et=t1 þ 2 et=t2  ð1Þ
CFP itself is known to have a multi-exponential de-
cay profile but here we approximated it to a mono-
exponential decay to simplify the fitting. This as-
sumption could be avoided if a donor with a mono-
exponential decay such as mTFP or mTurquoise was
to be used. We also approximated the complex decay
of the FRETing CFP donor observed when Gag-CFP
and Gag-YFP aggregate to form VLPs to a mo-
noexponential decay. The returned t2 values for
the homo- and hetero-FRET dose response were
766  9 ps and 713  25 ps respectively, where the er-
rors are the standard deviation of values obtained by
globally binning across each of the replicated rows of
the plate. Figure 5a shows the b1 (fraction of t1) plate
map for the homo- and hetero-FRET dose responses,
with Figures 5b and c showing the corresponding b1
values ( SD) when averaged over repeat wells. The
fraction of the long (b1) lifetime component (i.e. non-
FRETing donor) can be seen to increase with in-
creasing concentration of NMT inhibitor for both the
homo- and hetero-FRET dose responses, as ex-
pected. This analysis illustrates the potential to use a
global binning analysis of FLIM FRET data to esti-
mate the ratio of monomer/oligomerised Gag pro-
teins. We note this analysis would be more robust
when applied to FLIM FRET data from donors with
mono-exponential decays labelling proteins that di-
merise but do not form larger aggregates.
4. Conclusion
In conclusion, we have demonstrated the application
of an automated optically sectioning FLIM multiwell
plate reader to assay the aggregation of HIV Gag
protein during VLP formation. We have presented
the first application of dose response curves and the
Z0 parameter to evaluate the quantitative perform-
ance of FLIM assays. We have also reported the first
application of FLIM-based homo-FRET readouts of
Figure 5 (a) Plate map showing the mean fraction of long
lifetime component (b1) fitted across all FOVs for the
homo- and hetero-FRET doses responses; (b) and (c)
show the average b1 values ( SD) from all FOVs per con-
dition for homo- and hetero-FRET dose responses. See
Figure 4a for plating scheme.
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protein aggregation, noting that this may be limited
to complex fluorophores like CFP. The CFP homo-
FRET readout has several advantages over CFP/
YFP hetero-FRET including simplifying sample pre-
paration as well as increasing spectral efficiency,
which could be important for multiplexed readouts.
The changes in donor (CFP) fluorescence lifetime
observed in this study are relatively modest but pro-
vide robust readouts when averaged over the 96 well
plate data. We note that we were not able to obtain
such data on a standard TCSPC FLIM laser scan-
ning confocal microscope (LSCM) due to the prob-
lems with photobleaching and the much smaller sam-
ple numbers – noting that it is only practical to
image ~10 FOVs per hour with our manual FLIM
enabled LCSM. In contrast, our automated FLIM
plate reader can image a 96 well plate in ~10’s min-
utes total FLIM acquisition time (at 1 FOV per
well), depending on the brightness of the fluorophores
expressed and the extent to which the fluorescence
decays are sampled. We believe that this demonstra-
tion of the practicality of medium throughput optically
sectioned FLIM HCA shows that it could aid in the
optimization of lead compounds identified by HTS
systems as well as providing new opportunities for ba-
sic research in cell biology, particularly in the area of
PPIs. The ability to translate FLIM readouts from
automated plate readers to live disease models may
also have a positive impact on the drug discovery pipe-
line. In the immediate future we will utilise this new
capability to screen for other novel inhibitors of HIV
formation with a view to developing therapies for
HIVand other viral infections.
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